PTEN突变低分化甲状腺癌对mTOR抑制剂替西罗莫司联合纳武利尤单抗/伊匹木单抗双免疫治疗深度缓解：病例报告与文献综述 DataSheet_1

数据集获取（Figshare）

• 源站标题：DataSheet_1_Deep response to a combination of mTOR inhibitor temsirolimus and dual immunotherapy of nivolumab/ipilimumab in poorly differentiated thyroid carcinoma with PTEN mutation: a case report and literature review.pdf
• DOI：10.3389/fendo.2024.1304188.s001
• 发布日期：2024-01-31
• 文件数：1 个
• 文件总体积：753.70 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/DataSheet_1_Deep_response_to_a_combination_of_mTOR_inhibitor_temsirolimus_and_dual_immunotherapy_of_nivolumab_ipilimumab_in_poorly_differentiated_thyroid_carcinoma_with_PTEN_mutation_a_case_report_and_literature_review_pdf/25116110

命令行下载

curl -L -o "DataSheet_1_Deep response to a combination of mTOR inhibitor temsirolimus and dual immunotherapy of nivolumab/ipilimumab in poorly differentiated thyr.pdf" "https://ndownloader.figshare.com/files/44324372"

文件清单

• DataSheet_1_Deep response to a combination of mTOR inhibitor temsirolimus and dual immunotherapy of nivolumab/ipilimumab in poorly differentiated thyr.pdf（753.70 KB）

文件总体积 753.70 KB（源站 API 实测）。

数据说明

Treating advanced thyroid cancer presents challenges due to its resistance to various treatment modalities, thereby limiting therapeutic options. To our knowledge, this study is the first to report the efficacy of temsirolimus in conjunction with dual immunotherapy of nivolumab/ipilimumab to treat heavily treated advanced PDTC. A 50-year-old female initially presented with a rapidly enlarging mass on her right neck. Subsequent diagnosis revealed poorly differentiated thyroid carcinoma, leading to a total thyroidectomy followed by post-operative radioablation therapy. After four years, an examination for persistent cough revealed a recurrence of the disease within multiple mediastinal nodes. Genetic analysis of blood samples uncovered somatic mutations in the tumor, specifically involving PTEN and TP53. The disease progressed despite palliative radiation, lenvatinib, and nivolumab/ipilimumab therapy. Consequently, temsirolimus, functioning as an mTOR inhibitor, was introduced as an adjunct to the nivolumab/ipilimumab regimen. This combination approach yielded remarkable clinical improvement and disease control for a duration of approximately six months. Temsirolimus likely suppressed the aberrantly activated PI3K/AKT/mTOR signaling pathway, facilitated by the PTEN genetic alteration, thus engendering an effective treatment response. This synergy between targeted agents and immunotherapy presents a promising therapeutic strategy for advanced PDTC patients with limited treatment alternatives. In previous clinical trials, mTOR inhibitors have demonstrated the ability to maintain stable disease (SD) in 65% to 74% for advanced thyroid cancer patients, including those with PDTC. When combined with other targeted therapies, the observed SD or partial response rates range from 80% to 97%. Many of these trials primarily involved differentiated thyroid carcinoma, with diverse genetic mutations. Thyroid cancer patients with alterations in the PI3K/mTOR/Akt appeared to benefit most from mTOR inhibitors. However, no clear association between the efficacy of mTOR inhibitors and specific histologies or genetic mutations has been established. Future studies are warranted to eluc

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fendo.2024.1304188.s001（source: https://frontiersin.figshare.com/articles/dataset/DataSheet_1_Deep_response_to_a_combination_of_mTOR_inhibitor_temsirolimus_and_dual_immunotherapy_of_nivolumab_ipilimumab_in_poorly_differentiated_thyroid_carcinoma_with_PTEN_mutation_a_case_report_and_literature_review_pdf/25116110）。